Requadt Scott 4

4 · AVROBIO, Inc. · Filed Jun 25, 2018

Form 4

Period: 2018-06-25

Director

Transactions

Conversion
Common Stock
2018-06-25+678,891→ 2,962,325 total(indirect: See Footnote)
Conversion
Common Stock
2018-06-25+2,283,434→ 2,283,434 total(indirect: See Footnote)
Conversion
Series A Preferred Stock
2018-06-25−9,435,150→ 0 total(indirect: See footnote)
→ Common Stock (2,283,434 underlying)
Conversion
Series B Preferred Stock
2018-06-25−2,805,179→ 0 total(indirect: See footnote)
→ Common Stock (678,891 underlying)

Footnotes (4)

[F1]Represents the total number of shares of Common Stock received by Clarus Lifesciences III, L.P. ("Clarus") upon the conversion of the Issuer's Series A Preferred Stock in connection with the closing of the Issuer's initial public offering.
[F2]The shares are held directly by Clarus. The general partner of Clarus is Clarus Ventures III GP, L.P. ("GPLP"). Clarus Ventures III, LLC, ("LLC") is the general partner of GPLP. Each of Nicholas Galakatos, Dennis Henner, Robert Liptak, Scott Requadt, Nicholas Simon, and Kurt Wheeler, as individual managing directors of the LLC, may be deemed to beneficially own certain of the shares held of record by Clarus. Each of Messrs. Galakatos, Henner, Liptak, Requadt, Simon and Wheeler disclaims beneficial ownership of all shares held of record by Clarus in which he does not have an actual pecuniary interest. Mr. Requadt is a member of LLC and a member of the Issuer's board of directors. Mr. Requadt disclaims beneficial ownership of such shares, except to the extent of his proportionate pecuniary interest therein, if any.
[F3]Represents the total number of shares of Common Stock received by Clarus upon the conversion of the Issuer's Series B Preferred Stock in connection with the closing of the Issuer's initial public offering.
[F4]All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 4.132-for-1 basis on June 25, 2018 and had no expiration date.

Documents

1 file